Newron Pharmaceuticals (SIX: NWRN)

Last close As at 05/11/2025

CHF14.26

−0.04 (−0.28%)

Market capitalisation

CHF256m

Newron Pharmaceuticals is focused on the central nervous system. Xadago for Parkinson’s disease (PD) is sold in Europe, Japan, the United States and other regions. Evenamide, a novel schizophrenia add-on therapy, is involved in a Phase III trial programme targeting schizophrenia.

Latest Insights

View More

Healthcare | Flash

Newron Pharmaceuticals — ENIGMA-TRS 1 commences enrolment

Healthcare | edison tv

Newron Pharmaceuticals – executive interview

Sector

Healthcare

Equity Analyst

Jyoti Prakash

Jyoti Prakash, CFA

Director, healthcare

Key Management

  • Roberto Galli

    CFO

  • Stefan Weber

    CEO

  • Ravi Anand

    CMO

Further insights

insight

Healthcare

Newron Pharmaceuticals: EKF 2023 QuickView

insight

Healthcare

Deutsches Eigenkapitalforum (EKF) 2022 healthcare

insight

Consumer

Deutsches Eigenkapitalforum (EKF) 2022

Thematics